» Articles » PMID: 23533730

Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra

Overview
Journal AIDS Res Treat
Publisher Wiley
Date 2013 Mar 28
PMID 23533730
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial damage is implicated in highly active antiretroviral therapy (HAART) toxicity. HIV infection also causes mitochondrial toxicity (MT). Differentiating between the two is critical for HIV management. Our objective was to test the utility of the Mitochondrial Disease Criteria (MDC) and the Enquête Périnatale Française (EPF) to screen for possible HAART related MT in HIV-infected children in Ghana. The EPF and MDC are compilations of clinical symptoms, or criteria, of MT: a (+) score indicates possible MT. We applied these criteria retrospectively to 403 charts of HIV-infected children. Of those studied, 331/403 received HAART. Comparing HAART exposed and HAART naïve children, the difference in EPF score, but not MDC, approached significance (P = 0.1). Young age at HIV diagnosis or at HAART initiation was associated with (+) EPF (P ≤ 0.01). Adherence to HAART trended toward an association with (+) EPF (P = 0.09). Exposure to nevirapine, abacavir, or didanosine increased risk of (+) EPF (OR = 3.55 (CI = 1.99-6.33), 4.76 (2.39-9.43), 4.93 (1.29-18.87)). Neither EPF nor MDC identified a significant difference between HAART exposed or naïve children regarding possible MT. However, as indicators of HAART exposure are associated with (+) EPF, it may be a candidate for prospective study of possible HAART related MT in resource-poor settings.

Citing Articles

Chronic comorbidities in persons living with HIV within three years of exposure to antiretroviral therapy at Pantang Antiretroviral Center in Ghana: a retrospective study.

Kotey M, Alhassan Y, Adomako J, Nunoo-Mensah G, Kapadia F, Sarfo B Pan Afr Med J. 2022; 42:294.

PMID: 36415339 PMC: 9643783. DOI: 10.11604/pamj.2022.42.294.35134.


Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.

Jesson J, Saint-Lary L, Revegue M, ORourke J, Townsend C, Renaud F Lancet Child Adolesc Health. 2022; 6(10):692-704.

PMID: 36058225 PMC: 9474298. DOI: 10.1016/S2352-4642(22)00213-9.

References
1.
Moren C, Noguera-Julian A, Rovira N, Garrabou G, Nicolas M, Cardellach F . Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART. Antivir Ther. 2011; 16(5):719-24. DOI: 10.3851/IMP1806. View

2.
White A . Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001; 77(3):158-73. PMC: 1744319. DOI: 10.1136/sti.77.3.158. View

3.
Powderly W . Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr. 2002; 29 Suppl 1:S28-40. DOI: 10.1097/00126334-200202011-00005. View

4.
Miro O, Lopez S, Martinez E, Pedrol E, Milinkovic A, Deig E . Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis. 2004; 39(5):710-6. DOI: 10.1086/423176. View

5.
Montaner J, Cote H, Harris M, Hogg R, Yip B, Chan J . Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 34 Suppl 1:S85-90. DOI: 10.1097/00126334-200309011-00013. View